
Topic
Drug Pricing
WAC, ASP, NADAC, IRA negotiated prices, inflation rebates, and drug cost trends affecting access and coverage.

Generics· June 25, 2026 · 19 min read
By Ran Chen#Generics#Orange Book#FDA Approval

Generics· June 25, 2026 · 19 min read
Generic Gilenya: Dosing Patent Expiry and 99% Price Erosion
By Ran Chen#Generics#Orange Book#PBM

Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing

Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing

Generics· June 24, 2026 · 17 min read
Generic Entresto Market Entry: 95% Price Erosion and the Payer Formulary Transition
By Ran Chen#Generics#Generic Entry#Drug Pricing

Pricing & Access· June 24, 2026 · 25 min read
Novartis Portfolio Dossier: Spinoff Splits and Patent Cliffs
By Ran Chen#Orange Book#Purple Book#Generics

Generics· June 22, 2026 · 19 min read
Generic Vyvanse (Lisdexamfetamine): Shortage Status, API Quotas, and NADAC Price Erosion
By Ran Chen#Generics#Drug Pricing#Supply Chain

Generics· June 16, 2026 · 12 min read
Single-source transdermal patches in the Orange Book: 385 products, 43% no generic
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Manufacturing· June 15, 2026 · 11 min read
ADHD stimulant shortage: 222 records, 75 not fully available, 3-year median age

Manufacturing· June 14, 2026 · 10 min read